Cardiorenal end points in a trial of aliskiren for type 2 diabetes

Hans-Henrik Parving; Barry M Brenner; John J V McMurray; Dick de Zeeuw; Steven M Haffner; Scott D Solomon; Nish Chaturvedi; Frederik Persson; Akshay S Desai; Maria Nicolaides; Alexia Richard; Zhihua Xiang; Patrick Brunel; Marc A Pfeffer; ALTITUDE Investigators (members, Birger Thorsteinsson)

doi:10.1056/NEJMoa1208799

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

Hans-Henrik Parving, Barry M Brenner, John J V McMurray, Dick de Zeeuw, Steven M Haffner, Scott D Solomon, Nish Chaturvedi, Frederik Persson, Akshay S Desai, Maria Nicolaides, Alexia Richard, Zhihua Xiang, Patrick Brunel, Marc A Pfeffer, ALTITUDE Investigators (members, Birger Thorsteinsson)

1210 Citations (Scopus)

Abstract

This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both.

Original language	English
Journal	New England Journal of Medicine
Volume	367
Issue number	23
Pages (from-to)	2204-13
Number of pages	10
ISSN	0028-4793
DOIs	https://doi.org/10.1056/NEJMoa1208799
Publication status	Published - 2012

Keywords

Aged
Amides
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Cardiovascular Diseases
Diabetes Mellitus, Type 2
Double-Blind Method
Drug Therapy, Combination
Female
Follow-Up Studies
Fumarates
Humans
Hyperkalemia
Hypokalemia
Kidney Diseases
Male
Middle Aged
Patient Dropouts
Renin
Treatment Failure

Access to Document

10.1056/NEJMoa1208799

Cite this

Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., Richard, A., Xiang, Z., Brunel, P., Pfeffer, M. A., & ALTITUDE Investigators (members, Birger Thorsteinsson) (2012). Cardiorenal end points in a trial of aliskiren for type 2 diabetes. New England Journal of Medicine, 367(23), 2204-13. https://doi.org/10.1056/NEJMoa1208799

Parving, H-H, Brenner, BM, McMurray, JJV, de Zeeuw, D, Haffner, SM, Solomon, SD, Chaturvedi, N, Persson, F, Desai, AS, Nicolaides, M, Richard, A, Xiang, Z, Brunel, P, Pfeffer, MA & ALTITUDE Investigators (members, Birger Thorsteinsson) 2012, 'Cardiorenal end points in a trial of aliskiren for type 2 diabetes', New England Journal of Medicine, vol. 367, no. 23, pp. 2204-13. https://doi.org/10.1056/NEJMoa1208799

@article{326e60fb15324370a918e750c70a0026,

title = "Cardiorenal end points in a trial of aliskiren for type 2 diabetes",

abstract = "This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both.",

keywords = "Aged, Amides, Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Fumarates, Humans, Hyperkalemia, Hypokalemia, Kidney Diseases, Male, Middle Aged, Patient Dropouts, Renin, Treatment Failure",

author = "Hans-Henrik Parving and Brenner, \{Barry M\} and McMurray, \{John J V\} and \{de Zeeuw\}, Dick and Haffner, \{Steven M\} and Solomon, \{Scott D\} and Nish Chaturvedi and Frederik Persson and Desai, \{Akshay S\} and Maria Nicolaides and Alexia Richard and Zhihua Xiang and Patrick Brunel and Pfeffer, \{Marc A\} and \{ALTITUDE Investigators (members, Birger Thorsteinsson)\} and Birger Thorsteinsson",

year = "2012",

doi = "10.1056/NEJMoa1208799",

language = "English",

volume = "367",

pages = "2204--13",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "23",

}

TY - JOUR

T1 - Cardiorenal end points in a trial of aliskiren for type 2 diabetes

AU - Parving, Hans-Henrik

AU - Brenner, Barry M

AU - McMurray, John J V

AU - de Zeeuw, Dick

AU - Haffner, Steven M

AU - Solomon, Scott D

AU - Chaturvedi, Nish

AU - Persson, Frederik

AU - Desai, Akshay S

AU - Nicolaides, Maria

AU - Richard, Alexia

AU - Xiang, Zhihua

AU - Brunel, Patrick

AU - Pfeffer, Marc A

AU - ALTITUDE Investigators (members, Birger Thorsteinsson)

A2 - Thorsteinsson, Birger

PY - 2012

Y1 - 2012

N2 - This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both.

AB - This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both.

KW - Aged

KW - Amides

KW - Angiotensin Receptor Antagonists

KW - Angiotensin-Converting Enzyme Inhibitors

KW - Antihypertensive Agents

KW - Cardiovascular Diseases

KW - Diabetes Mellitus, Type 2

KW - Double-Blind Method

KW - Drug Therapy, Combination

KW - Female

KW - Follow-Up Studies

KW - Fumarates

KW - Humans

KW - Hyperkalemia

KW - Hypokalemia

KW - Kidney Diseases

KW - Male

KW - Middle Aged

KW - Patient Dropouts

KW - Renin

KW - Treatment Failure

UR - https://www.scopus.com/pages/publications/84869492851

U2 - 10.1056/NEJMoa1208799

DO - 10.1056/NEJMoa1208799

M3 - Journal article

C2 - 23121378

SN - 0028-4793

VL - 367

SP - 2204

EP - 2213

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 23

ER -

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this